Benefits of Lovenox in the management of risk coronary syndrome patients without large ST-segment elevation
The results of the UA Submission / NSTEMI in ACC test launch of Aventis in Strasbourg, France, the results of a landmark study of 10,027 patients, showed that Lovenox (enoxaparin sodium) is effective as unfractionated heparin (UFH) in the treatment of high risk patients with non-ST acute coronary syndrome (ACS) undergoing a rapid invasive strategy. SYNERGY study results were presented today at a meeting last minute clinical trials at the American College of Cardiology Annual Scientific Session 2004.The results of previous studies provide strong evidence for the superiority of enoxaparin over unfractionated heparin in medically managed patients with ACS, said Robert Califf, MD, Associate Vice Chancellor for Clinical Research, Director of Duke Clinical Research Institute at
Duke University Medical Center, Durham, NC, and a senior researcher of the study. Now, according to data from SYNERGY benefit with enoxaparin in aggressive management of these high-risk population. Physicians should not hesitate to patients in transition enoxaparin during percutaneous coronary intervention .In this patient group founded to Lovenox at least as effective as unfractionated heparin in reducing the incidence of death or myocardial infarction at 30 days, the primary endpoint (14.0 percent vs. 14.5 percent NS p). SYNERGY security was the GUSTO and TIMI major bleeding, transfusion rate, intracranial hemorrhage (ICH) and bleeding assessed hemodynamic instability. The results showed that the incidence of GUSTO severe bleeding 2.9% vs 2.4% UFH Lovenox (SNP).The
incidence of TIMI major non-CABG was 2.4% versus 1.7% (p 0.025), a statistically significant difference. The incidence of bleeding was confused for extended anticoagulant change. Importantly, there was no difference in the frequency of blood transfusions, ME and unexpected.Patients started on Lovenox and had better results A secondary analysis of 5637 patients in SYNERGY showed that those who began treatment with Lovenox
Pages: [1] 2 3